{"nctId":"NCT02569242","briefTitle":"Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer","startDateStruct":{"date":"2015-12-14","type":"ACTUAL"},"conditions":["Esophageal Cancer"],"count":419,"armGroups":[{"label":"Nivolumab Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Nivolumab"]},{"label":"Active Comparator Arm （Docetaxel/Paclitaxel）","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel/Paclitaxel"]}],"interventions":[{"name":"Nivolumab","otherNames":[]},{"name":"Docetaxel/Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men \\& women ≥20 years of age\n* Histologically confirmed unresectable advanced or recurrent esophageal cancer\n* Refractory to or intolerant of standard therapy\n* ECOG Performance Status score 0 or 1\n* A life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Current or past history of severe hypersensitivity to any other antibody products\n* Patients with multiple primary cancers\n* Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment\n* Patients with active, known or suspected autoimmune disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of \"Not Evaluable (NE).\"","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of \"Not Evaluable (NE).\"","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":68,"n":209},"commonTop":["Decreased appetite","Alopecia","Anaemia","Neutrophil count decreased","Constipation"]}}}